\BOOKMARK [0][-]{chapter.1}{Introduction: Nanoparticles in medicine and biology}{}% 1
\BOOKMARK [1][-]{section.1.1}{Polymeric colloids}{chapter.1}% 2
\BOOKMARK [2][-]{subsection.1.1.1}{Functionalization for protein binding}{section.1.1}% 3
\BOOKMARK [2][-]{subsection.1.1.2}{Polymerization consequences}{section.1.1}% 4
\BOOKMARK [1][-]{section.1.2}{Liposomal nanocarriers}{chapter.1}% 5
\BOOKMARK [2][-]{subsection.1.2.1}{Phospholipid bilayer}{section.1.2}% 6
\BOOKMARK [2][-]{subsection.1.2.2}{polydispersity control}{section.1.2}% 7
\BOOKMARK [2][-]{subsection.1.2.3}{Drug carrier and SSLs}{section.1.2}% 8
\BOOKMARK [1][-]{section.1.3}{Physicochemical characterization}{chapter.1}% 9
\BOOKMARK [2][-]{subsection.1.3.1}{Dimensional metrology and traceability}{section.1.3}% 10
\BOOKMARK [2][-]{subsection.1.3.2}{Characterization tools}{section.1.3}% 11
\BOOKMARK [0][-]{chapter.2}{Theoretical Background}{}% 12
\BOOKMARK [1][-]{section.2.1}{Interaction of light and matter}{chapter.2}% 13
\BOOKMARK [2][-]{subsection.2.1.1}{Beer-Lamber Law}{section.2.1}% 14
\BOOKMARK [2][-]{subsection.2.1.2}{X-ray cross sections}{section.2.1}% 15
\BOOKMARK [2][-]{subsection.2.1.3}{Thompson scattering}{section.2.1}% 16
\BOOKMARK [2][-]{subsection.2.1.4}{Rayleight and Mie scattering}{section.2.1}% 17
\BOOKMARK [1][-]{section.2.2}{Small-angle X-ray scattering}{chapter.2}% 18
\BOOKMARK [2][-]{subsection.2.2.1}{Physical process}{section.2.2}% 19
\BOOKMARK [2][-]{subsection.2.2.2}{Evaluation of the scattering intensity}{section.2.2}% 20
\BOOKMARK [1][-]{section.2.3}{Contrast variation}{chapter.2}% 21
\BOOKMARK [2][-]{subsection.2.3.1}{Isoscattering point}{section.2.3}% 22
\BOOKMARK [2][-]{subsection.2.3.2}{Basic functions approach}{section.2.3}% 23
\BOOKMARK [1][-]{section.2.4}{Dynamic Light Scattering}{chapter.2}% 24
\BOOKMARK [0][-]{chapter.3}{Instrumentation and experimental setup for SAXS measurements}{}% 25
\BOOKMARK [1][-]{section.3.1}{BESSY II}{chapter.3}% 26
\BOOKMARK [2][-]{subsection.3.1.1}{Insertion devices}{section.3.1}% 27
\BOOKMARK [1][-]{section.3.2}{FCM Beamline}{chapter.3}% 28
\BOOKMARK [2][-]{subsection.3.2.1}{UHV X-ray Reflectometer}{section.3.2}% 29
\BOOKMARK [1][-]{section.3.3}{SAXS Setup}{chapter.3}% 30
\BOOKMARK [2][-]{subsection.3.3.1}{X-ray area detector}{section.3.3}% 31
\BOOKMARK [2][-]{subsection.3.3.2}{HZB SAXS instrument and WAXS configuration}{section.3.3}% 32
\BOOKMARK [1][-]{section.3.4}{Sample environment}{chapter.3}% 33
\BOOKMARK [2][-]{subsection.3.4.1}{Round capillaries}{section.3.4}% 34
\BOOKMARK [2][-]{subsection.3.4.2}{Rectangular capillaries}{section.3.4}% 35
\BOOKMARK [2][-]{subsection.3.4.3}{Cell for low-energies}{section.3.4}% 36
\BOOKMARK [1][-]{section.3.5}{Data reduction: The scattering curve}{chapter.3}% 37
\BOOKMARK [1][-]{section.3.6}{Small-angle X-ray scattering: DIRECT FROM PAPER}{chapter.3}% 38
\BOOKMARK [2][-]{subsection.3.6.1}{Filling of capilaries}{section.3.6}% 39
\BOOKMARK [2][-]{subsection.3.6.2}{Calibration of solvent density and finding of main axis}{section.3.6}% 40
\BOOKMARK [2][-]{subsection.3.6.3}{Limitations}{section.3.6}% 41
\BOOKMARK [0][-]{chapter.4}{Contrast variation in SAXS with the density gradient technique}{}% 42
\BOOKMARK [1][-]{section.4.1}{Materials and Methods}{chapter.4}% 43
\BOOKMARK [2][-]{subsection.4.1.1}{Particles and chemicals}{section.4.1}% 44
\BOOKMARK [2][-]{subsection.4.1.2}{Diffusion time and calibration height}{section.4.1}% 45
\BOOKMARK [1][-]{section.4.2}{Continuous contrast variation in SAXS on PS-COOH colloids}{chapter.4}% 46
\BOOKMARK [1][-]{section.4.3}{Model dependent evaluation}{chapter.4}% 47
\BOOKMARK [2][-]{subsection.4.3.1}{Core-shell form factor fit}{section.4.3}% 48
\BOOKMARK [1][-]{section.4.4}{Model-free approach to contrast variation data}{chapter.4}% 49
\BOOKMARK [2][-]{subsection.4.4.1}{Isoscattering point}{section.4.4}% 50
\BOOKMARK [2][-]{subsection.4.4.2}{Guinier region}{section.4.4}% 51
\BOOKMARK [1][-]{section.4.5}{Summary}{chapter.4}% 52
\BOOKMARK [0][-]{chapter.5}{Simultaneous size and density determination of polymeric colloids}{}% 53
\BOOKMARK [1][-]{section.5.1}{Materials and methods}{chapter.5}% 54
\BOOKMARK [2][-]{subsection.5.1.1}{Particles and chemicals}{section.5.1}% 55
\BOOKMARK [2][-]{subsection.5.1.2}{Differential Centrifuge Sedimentation \(DCS\)}{section.5.1}% 56
\BOOKMARK [1][-]{section.5.2}{Technique validation for the determination of the particle size distribution}{chapter.5}% 57
\BOOKMARK [2][-]{subsection.5.2.1}{Inter-laboratory comparison of the mean particle size}{section.5.2}% 58
\BOOKMARK [2][-]{subsection.5.2.2}{Colloidal size distribution}{section.5.2}% 59
\BOOKMARK [1][-]{section.5.3}{Considerations about contrast variation data evaluation}{chapter.5}% 60
\BOOKMARK [2][-]{subsection.5.3.1}{Shape factor formalism}{section.5.3}% 61
\BOOKMARK [2][-]{subsection.5.3.2}{Isoscattering point approach}{section.5.3}% 62
\BOOKMARK [1][-]{section.5.4}{Determination of the particle physical density}{chapter.5}% 63
\BOOKMARK [2][-]{subsection.5.4.1}{Validation through comparison with DCS}{section.5.4}% 64
\BOOKMARK [2][-]{subsection.5.4.2}{Use for homogenous polymeric colloids}{section.5.4}% 65
\BOOKMARK [1][-]{section.5.5}{Summary}{chapter.5}% 66
\BOOKMARK [0][-]{chapter.6}{Continuous contrast variation applied to relevant bio-materials}{}% 67
\BOOKMARK [1][-]{section.6.1}{Materials and methods}{chapter.6}% 68
\BOOKMARK [2][-]{subsection.6.1.1}{Caelyx\256: PEGylated liposomal doxorubicin}{section.6.1}% 69
\BOOKMARK [2][-]{subsection.6.1.2}{Lipid vesicles: PEGylated and plain liposomes}{section.6.1}% 70
\BOOKMARK [2][-]{subsection.6.1.3}{Human lipoproteins}{section.6.1}% 71
\BOOKMARK [2][-]{subsection.6.1.4}{PS-COOH particles coated with IgG}{section.6.1}% 72
\BOOKMARK [1][-]{section.6.2}{Traceable size determination of a liposomal drug}{chapter.6}% 73
\BOOKMARK [2][-]{subsection.6.2.1}{Isoscattering point approach}{section.6.2}% 74
\BOOKMARK [2][-]{subsection.6.2.2}{Shape factor calculation}{section.6.2}% 75
\BOOKMARK [2][-]{subsection.6.2.3}{Average electron density}{section.6.2}% 76
\BOOKMARK [1][-]{section.6.3}{Osmotic effects in liposomes}{chapter.6}% 77
\BOOKMARK [2][-]{subsection.6.3.1}{Application to drug-stabilized liposomes}{section.6.3}% 78
\BOOKMARK [2][-]{subsection.6.3.2}{Does PEGylation affect the osmotic activity of liposomes?}{section.6.3}% 79
\BOOKMARK [1][-]{section.6.4}{Sizing of blood plasma componenents}{chapter.6}% 80
\BOOKMARK [1][-]{section.6.5}{Protein-coated low-density nanoparticles}{chapter.6}% 81
\BOOKMARK [2][-]{subsection.6.5.1}{Hard protein corona characterization with contrast variation}{section.6.5}% 82
\BOOKMARK [1][-]{section.6.6}{Summary}{chapter.6}% 83
